Maxim Upgrades Gilead Sciences to Buy, Sees 20% Upside
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
gilead-sciencesmaxim-group
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Maxim Group announced on 24 May 2026 that it upgraded its rating on Gilead Sciences Inc. (GILD) to Buy from Hold. The firm assigned a price target of $112 per share. This target suggests a nearly 20% upside from the stock's closing price of approximately $93.50 on 23 May 2026. The upgrade reflects a reassessment of the company's oncology portfolio growth and capital allocation strategy.
Analyst upgrades from Hold to Buy are significant for large-cap biotechs like Gilead, which has a market capitalization exceeding $110 billion. The last major upgrade for Gilead occurred in February 2025 when Leerink Partners moved to Outperform, citing execution in cell therapy. That upgrade preceded a 15% stock rally over the subsequent six months.
The current macro backdrop features stable long-term Treasury yields near 4.2% and persistent demand for defensive, cash-generative healthcare names. Gilead's dividend yield of 3.9% remains attractive relative to the 10-year Treasury. The immediate catalyst for Maxim's reassessment is the firm's updated model incorporating first-quarter 2026 sales data for Trodelvy and Biktarvy.
Maxim's model now projects stronger-than-consensus sales growth for Trodelvy in metastatic breast and bladder cancers. The analyst team also noted Gilead's improved free cash flow generation, which supports ongoing share repurchases. This financial stability reduces perceived risk amid broader market volatility, making the upgrade timely for institutional reallocations.
Gilead's stock closed at $93.48 on 23 May, the day before the upgrade. The new $112 price target implies a 19.8% potential return. Gilead shares have gained 12% year-to-date, outperforming the iShares Biotechnology ETF (IBB), which is up 8% over the same period. The company's forward price-to-earnings ratio stands at 13.5, a discount to the S&P 500 healthcare sector average of 16.2.
Revenue for the first quarter of 2026 totaled $7.1 billion. HIV product sales contributed $4.5 billion, while oncology sales reached $950 million. The company generated $2.8 billion in operating cash flow for the quarter. Gilead's net debt-to-EBITDA ratio improved to 1.6x, down from 1.9x a year prior.
| Metric | Pre-Upgrade View (Hold) | Post-Upgrade View (Buy) |
|---|---|---|
| 2026 EPS Estimate | $7.45 | $7.68 |
| 2027 Oncology Sales | $4.1B | $4.5B |
| Target Price | Not Disclosed | $112 |
This revision places Maxim's 2027 earnings estimate 3% above the current Wall Street consensus.
The upgrade reinforces positive sentiment toward large-cap biopharma companies with diversified revenue and strong dividends. Direct beneficiaries include sector peers like Bristol-Myers Squibb (BMY) and Amgen (AMGN), which trade at similar valuation discounts. In contrast, earlier-stage oncology-focused biotechs like Exelixis (EXEL) may face increased competition for investor capital as funds rotate into more stable names.
A key risk to the bullish thesis is the potential for faster-than-expected price erosion in the HIV franchise due to biosimilar competition later in the decade. Pipeline setbacks for Trodelvy in earlier-line cancer settings could also invalidate the sales growth assumptions. The counter-argument is that Gilead's valuation already discounts these risks, providing a margin of safety.
Positioning data indicates institutional investors have been net buyers of Gilead over the past quarter. Flow is moving from pure-play mRNA vaccine makers and COVID-19 therapeutics toward companies with visible long-term cash flows. The upgrade may trigger additional buying from mid-cap growth funds that have underweighted the stock.
The next major catalyst is Gilead's second-quarter 2026 earnings report, scheduled for 30 July 2026. Analysts will scrutinize Trodelvy sales figures and any updates on the Phase 3 EVOKE-03 trial for Trodelvy in lung cancer. The American Society of Clinical Oncology (ASCO) annual meeting in June 2026 may provide new clinical data readouts.
Investors should watch the $95 resistance level, a point the stock has tested and failed to hold twice in 2026. A sustained break above this level could target the $100 psychological barrier. On the downside, support lies near the 200-day moving average at $88.50. The 10-year Treasury yield remaining below 4.5% would support the dividend investment case.
If the Federal Reserve signals a rate cut at its September 2026 meeting, high-yielding healthcare stocks like Gilead could see multiple expansion. Conversely, a resurgence in inflation expectations pushing yields above 4.5% would pressure the sector's relative appeal.
For retail investors, the upgrade highlights Gilead as a candidate for both income and potential growth. The 3.9% dividend yield is a source of return regardless of short-term price movement. The $112 price target provides a clear valuation benchmark. Retail investors should note that analyst targets are estimates, not guarantees, and the stock's performance will ultimately depend on quarterly execution and pipeline progress.
Maxim's upgrade is the second Buy-equivalent initiation or upgrade for Gilead in 2026. In March 2026, Barclays reaffirmed its Overweight rating with a $105 target. The consensus rating among 25 analysts tracked by Bloomberg remains Hold, with 12 Buys, 10 Holds, and 3 Sells. Maxim's $112 target is the highest among major firms, exceeding the median target of $102 and the average target of $100.50.
Maxim Group has a focused healthcare practice. An analysis of its 15 major upgrades (Hold to Buy or equivalent) on large-cap biopharma stocks over the past five years shows that, on average, the upgraded stock outperformed the IBB biotech ETF by 4 percentage points over the following 90 days. However, the success rate is approximately 60%, meaning four out of ten upgrades did not lead to relative outperformance, underscoring the importance of broader market conditions.
Maxim's upgrade signals growing conviction that Gilead's oncology growth can outweigh HIV franchise risks, supporting a 20% re-rating.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.